Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Age and gender bias in statin trials
Autore:
Bandyopadhyay, S; Bayer, AJ; OMahony, MS;
Indirizzi:
Llandough Hosp, Acad Ctr, Univ Dept Geriatr Med, Penarth CF64 2XX, S Glam,Wales Llandough Hosp Penarth S Glam Wales CF64 2XX narth CF64 2XX, S Glam,Wales
Titolo Testata:
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS
fascicolo: 3, volume: 94, anno: 2001,
pagine: 127 - 132
SICI:
1460-2725(200103)94:3<127:AAGBIS>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY HEART-DISEASE; AVERAGE CHOLESTEROL LEVELS; MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENTS; ARTERY DISEASE; OLDER PERSONS; PRAVASTATIN; ATHEROSCLEROSIS; LOVASTATIN; PROGRESSION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: O'Mahony, MS Llandough Hosp, Acad Ctr, Univ Dept Geriatr Med, 3rd Floor,Penlan Rd, Penarth CF64 2XX, S Glam, Wales Llandough Hosp 3rd Floor,Penlan RdPenarth S Glam Wales CF64 2XX
Citazione:
S. Bandyopadhyay et al., "Age and gender bias in statin trials", QJM-MON J A, 94(3), 2001, pp. 127-132

Abstract

Cardiovascular disease is strongly age-related, and is the leading cause of death in older people, Several well-publicized trials have recently reported that statin drugs (HMG CoA reductase inhibitors) are effective in lowering cholesterol and in reducing the risk of myocardial infarction and stroke. In order to determine whether the results of these trials are relevant to our ageing population, we examined the representation of older people andwomen in randomized controlled trials of statin drugs. A systematic searchof the medical literature from 1990 to 1999 was done to identify randomized placebo-controlled trials of statin drugs which evaluated clinical end-points-myocardial infarction, stroke or death. We identified 19 trials: 15 secondary prevention and four primary prevention. The mean age, age range andgender of the participants in these trials were determined. In the secondary prevention trials, the total number of patients randomized was 31 683, with a combined mean age of 58.1 years. No trial enrolled people beyond the age of 75 years, and only 23% of the trial population was female. The four primary prevention trials randomized a combined total of 14 557 subjects with a mean age of 56.9 years. Only 10% of study participants were female. Statin drug trials have suffered From age and gender bias, having been mainlyconducted in middle-aged male populations. The extrapolation of evidence from these trials to older people and women needs further evaluation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 22:23:33